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Summary Valproic acid (VPA) is considered to be a drug of first choice for the
therapy of generalized and focal epilepsies, including special epileptic syndromes like
the WEST-syndrome. The drug is usually well tolerated; rare serious complications
may occur in some patients, including haemorrhagic pancreatitis, coagulapathies,
bone marrow suppression, VPA-induced hepatotoxicity and encephalopathy. We
report a case of combined appearance of several severe VPA-associated side effects
in a two- and a half-year-old girl with lissencephaly.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Case
Because of partial lissencephaly the former 28 week
of gestation, neonate suffered from a West-syn-
drome with continuous hypsarrhythmia and 5—10
typical seizures per day. At the age of 3 months we
initiated an antiepileptic therapy with topiramate
(TPM), supplemented by VPA at the age of 14
months. With a contenting influence on the seizures
the medication was well tolerated. At the age of 19
months seizure frequency increased again and we
added vigabatrine to the above named antiepileptic
medication. One month later, the vigabatrine med-* Corresponding author. Tel.: +49 6213 832466.
E-mail address: thorsten-gerstner@web.de (T. Gerstner).
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doi:10.1016/j.seizure.2007.04.003ication was withdrawn because of insufficient effec-
tiveness. Lamotrigine (LTG) was then added to TPM
and VPA (LTG 7 50mg/day, TPM 100 mg/day, VPA
900 mg/day).
The EEG showed discontinuous hypsarrhythmia
with depressed periods under 30 mV at this time.
At the age of two and a half, the girl was pre-
sented at the paediatric ward of our hospital with
increased seizure frequency, augmented fatigue,
fever and vomiting. On examination the girl
appeared moderately ill, but the mother was wor-
ried about a significant reduction in alertness and
attention. Additionally the seizure frequency was
increased up to 20—30 short focal seizures per day.
The girl did not take any additional medication than
the antiepileptic drugs.. Published by Elsevier Ltd. All rights reserved.
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Table 1 Overview laboratory findings
Laboratory findings while
presented at the paediatric ward
Laboratory findings 10 day after
VPA-level (60—120) 87 mg/l —
Ammonia (11—48) 47 mmol/l 39 mmol/l
ALAT/ASAT (35/43) 2510 U/l/6900 U/l 65 U/l/45 U/l
Lipase (114—286) 725 U/l 159 U/l
Platelets (200,000—400,000) 41,000/ml 220,000/ml
White blood cells (5300—11,300) 3.500/ml 8900/ml
Haemoglobin (10.7—12.7);
red Blood cells (4.0—4.9)
hb 9.6 g/dl, RBC 2.1 Mill./ml hb 12.1 g/dl, RBC 3.88 Mill./ml
Quick-ratio (70—130) 47% 92%
Plasma-albumin (35—52) 22 g/l 26 g/lThe laboratory investigations showed changes in
transaminases, lipase, white blood count (WBC),
platelets and coagulation parameters. Additionally,
we found elevated serum ammonia level and focal
temporal slowing (theta—delta activity) in the EEG,
in contrast to former EEG findings (shown in Table 1).
The Serum—VPA level was 87 mg/l.
We immediately stopped the VPA medication and
initiated an intravenous carnitine therapy (100 mg/
kg/BW). When signs of hepatotoxicity occur, it is
decisive to withdraw VPA early and substitute i.v.
carnitine immediately.1 Especially changes in citrul-
linogenesis or in other steps of the urea cycle within
VPA benefit by an early use of carnitin.2
To exclude an infectious meningitis or encephali-
tis, a lumbar puncture was performed without any
pathological findings. An X-ray of the chest presented
pneumonia pronounced on the right lung, intrave-
nous Cefuroxim 100 mg/kg was administered.
In the Course of the next 10 days the medical
condition aswell as the laboratory findings improved.
The antiepileptic medication was continued with
LTG and TPM in unmodified dosages. The focal slow-
ing at the EEG vanished, the seizure frequency
remained acceptable and the girl’s vigilance nor-
malized.Conclusion
In most cases, VPA is a well-tolerated antiepileptic
drug with high effectiveness in seizure control. Most
of the side effects are mild and transient, but there
are also rare but severe side effects, especially
hepatotoxicity,3 encephalopathy,4 coagulation disor-
ders, 5 pancreatitis 6 and bone marrow suppression.7
In our case of a two- and a half-year-old girl, we
found a combination of encephalopathy, bone mar-
row suppression, hepatopathy and mild pancreati-
tis, associated with a VPA-therapy, supposedly
triggered off by a simultaneous infection.Interestingly, the girl previously showed a few
serious infections in combination with the antiepi-
leptic medication, but never before did severe VPA-
associated side effects appear. According to pre-
vious publications, VPA-associated side effects van-
ish rapidly under withdrawal of VPA and intravenous
therapy with carnitine.1
Especially during infections, the physicians
should show specific advertence to VPA-associated
problems. An overhaul of parameters like blood
count, coagulation parameters, transaminases,
ammonia and pancreatic enzymes is necessary,
the EEG could provide further indices of a VPA-
associated encephalopathy.
In case of such side effects, an immediate with-
drawal is required and a supportive therapy with
intravenous carnitine is necessary.
In consideration of this approach, the side effects
vanish and the patients’ outcome is proper.
Multiple severe side effects associated with VPA
therapy are well known from the fatalities that had
occurred in the 1970s and 1980s. Hepatotoxicity and
encephalopathy are most focused upon, but many
patients had other related disorders.
Pancreatitis was considered to be unrelated to
VPA by Dreifuss,8 but in the meantime we learned
that it is common in patients treated with VPA. In
the early patients, lipase and amylase were some-
times not even determined, but in some patients
pancreatitis was diagnosed only at autopsy.9
Similarly, the complex influence of VPA on coa-
gulation was not known at the time. Von Willebrand
Ju¨rgens factor, ristocetin-Co-factor and factor XIII
were never measured in the early patients, blood
counts were not focused upon. One of the patients
described by Ward,10 however, reported as a patient
with Hepatotoxicity, in fact died from a cerebral
haemorrhage related to severe thrombocytopenia
with some accompanying hepatoxicity. In this
patient, bone marrow suppression and hepatoxicity
also co-existing simultaneously.
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side effects related to VPA survived. As VPA was
withdrawn whenever anyone of the possible symp-
toms occurred, the large majority of the patients
had one or two prevailing symptoms such as hepa-
totoxicity,3 pancreatitis,11 coagulation disorder 5
and bone marrow suppression.7
Our patient is unusual as she reported the various
possible side effects in a short period of time. More-
over, all symptoms were reversible, which has not
been described in the literature before. The pattern
of the simultaneous side effects is remarkable as
many different pathophysiological mechanisms are
affected at the same time:- Hepatotoxicity: known or unknown metabolic
defect or metabolic abnormalities, breakdown
of the energy metabolism, depletion of intracel-
lular CoA.
 Disruption of membranes with elevation of ASAT
and ALAT.
 Altered synthesis of coagulation factor pro-
teins.- Pancreatitis: altered membranes, possibly due to
impaired lipid Peroxidase.- Encephalopathy: with hyperammonemia, but also
without hyperammonemia, possible direct influ-
ence of VPA on neurotransmitters.- Bonemarrow suppression: totally unrelated to the
other side effects, may affect some cell lines
selectively, i.e. isolated thrombocytopenia,5 leu-
copenia,12 anaemia,13 or any combination above.
This effect could be related to the effects of VPA
directly on the activation of genes, but also the
inhibition of histone-decarboxylase. It is supposa-
ble that the slight reduction of erythrocytes with
an increased MCV could be due to the same
mechanism.
At this time, we do not understand why most
patients never have any side effects related to VPA
and why other patients show such a variety of side
effects related to different mechanisms.Our patient emphasizes nevertheless that all
possible side effects have to be looked for an indi-
vidual patient and that they may be totally rever-
sible after withdrawal of VPA. Additionally, if one
severe VPA-associated side effect appears, the pos-
sibility of an accompanying secondary side effect is
considerable.References
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